InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | 2026-03-13 | Ryan Barbara | Director | Purchase | 8 | $31.09 | $248.68 | 5,724 | View ↗ | |
| 2026-03-09 | 2026-03-11 | Ryan Barbara | Director | Purchase | 31 | $32.56 | $1K | 5,716 | View ↗ | |
| 2026-03-06 | 2026-03-11 | Kingsley Stuart A | Director | Purchase | 940 | $31.86 | $30K | 5,582 | View ↗ |
| Metric | FY2025 | FY2024 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Net revenue | — | $1.24B+4.3% | $1.19B+8.7% | $1.09B | — |
| Cost of sales | — | $246.0M+6.5% | $231.0M+32.8% | $174.0M | — |
| Gross profit | — | $994.0M+3.9% | $957.0M+4.1% | $919.0M | — |
| Selling, general and administrative | $634.0M+262.3% | $175.0M+23.2% | $142.0M-6.6% | $152.0M+6.3% | $143.0M |
| Research and development | — | $97.0M-9.3% | $107.0M-7.8% | $116.0M | — |
| Acquired in-process research and development | — | $0-100.0% | $1.0M-99.4% | $162.0M | — |
| Litigation settlement | — | $3.0M-98.5% | $195.0M-18.4% | $239.0M | — |
| Other operating (income) expense, net | — | -$3.0M-175.0% | $4.0M+144.4% | -$9.0M | — |
| Operating income (loss) | $262.0M+469.6% | $46.0M+31.4% | $35.0M+129.7% | -$118.0M-257.3% | $75.0M |
| Interest income | — | -$22.0M+4.3% | -$23.0M+46.5% | -$43.0M | — |
| Interest expense | — | $45.0M+9.8% | $41.0M+17.1% | $35.0M | — |
| Income (loss) before income taxes | $239.0M+528.9% | $38.0M+26.7% | $30.0M+124.8% | -$121.0M-265.8% | $73.0M |
| Income tax expense (benefit) | $29.0M+70.6% | $17.0M+112.5% | $8.0M+134.8% | -$23.0M-309.1% | $11.0M |
| Net income (loss) | $210.0M+900.0% | $21.0M-4.5% | $22.0M+122.7% | -$97.0M-259.0% | $61.0M |
| Basic (in dollars per share) | — | $1.7M+3260.0% | $50K+105.4% | -$920K | — |
| Diluted (in dollars per share) | — | $1.6M+3180.0% | $50K+105.4% | -$920K | — |
| Basic (in shares) | — | $125.0M-5.3% | $132.0M-3.6% | $137.0M | — |
| Diluted (in shares) | — | $133.0M+0.0% | $133.0M-2.9% | $137.0M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%